Blar i forfatter "Helland, Åslaug"

Viser treff 1-13 av 13

    • Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT-1 trial 

      Horndalsveen, Henrik; Alver, Tine Norman; Dalsgaard, Astrid Marie; Helbekkmo, Nina; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Ramberg, Christina; Haakensen, Vilde Drageset; Øjlert, Åsa Kristina; Bjaanæs, Maria Moksnes; Helland, Åslaug; Rogg, Lotte Victoria (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-11-04)
      The introduction of immune checkpoint inhibitors has transformed the treatment landscape of metastatic non-small cell lung cancer. However, challenges remain to increase the fraction of patients achieving durable clinical responses to these drugs and to help monitor the treatment effect. In this phase II trial, we investigated the toxicity, systemic responses and circulating tumour DNA responses in ...

    • Circulating T Cell Activation and Exhaustion Markers Are Associated With Radiation Pneumonitis and Poor Survival in Non-Small-Cell Lung Cancer 

      Berg, Janna; Halvorsen, Ann Rita; Bengtson, May-Bente; Lindberg, Morten; Halvorsen, Bente; Aukrust, Pål; Helland, Åslaug; Ueland, Thor (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-07-14)
      Introduction: Persistent inflammation and immune activation in the lungs are associated with adverse outcomes such as radiation pneumonitis (RP) and poor survival in non-small-cell lung cancer (NSCLC) patients. However, it is unknown how this is reflected by leukocyte activation markers in serum.<p> <p>Objective: The aim was to evaluate the serum levels of activation of different leukocyte subsets ...

    • Clinical significance of disseminated tumour cells in non-small cell lung cancer 

      Rud, Ane Kristine Kongsgaard; Borgen, Elin; Mælandsmo, Gunhild; Flatmark, Kjersti; Le, Hang Ngoc Thi; Josefsen, Dag; Solvoll, Ingjerd; Schirmer, Cecilie; Helland, Åslaug; Jørgensen, Lars Hilmar; Brustugun, Odd Terje; Fodstad, Øystein; Boye, Kjetil (Journal article; Tidsskriftartikkel; Peer reviewed, 2013-08-13)
      Background: Early-stage non-small cell lung cancer (NSCLC) patients have a high risk of disease relapse despite curatively intended surgical resection, and the detection of tumour cells in the bone marrow could be one method of determining the presence of the disseminated disease in its early stages.<p> <p>Methods: Bone marrow aspirates were collected from 296 patients at the time of surgery, and ...

    • Concordance between clinical and pathology TNM-staging in lung cancer 

      Solberg, Steinar; Nilssen, Yngvar; Brustugun, Odd Terje; Haram, Per Magnus; Helland, Åslaug; Møller, Bjørn; Strand, Trond-Eirik; Wahl, Sissel Gyrid Freim; Fjellbirkeland, Lars (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-07-25)
      Objectives: A prerequisite for utilizing the tumour, lymph-nodes, and metastases (TNM) for the staging of lung cancer patients is a high quality of the reported data on which the staging is based. The aim of this study was to investigate the concordance between the clinical, cTNM and the pathology, pTNM staging for lung cancer, version 8 as reported to the Cancer Registry of Norway (CRN).<p> < ...

    • Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer 

      Rud, Ane Kristine Kongsgaard; Pedersen, Kjetil Boye; Fodstad, Øystein; Juell, Siri; Jørgensen, Lars Hilmar; Solberg, Steinar; Helland, Åslaug; Brustugun, Odd Terje; Mælandsmo, Gunhild (Journal article; Tidsskriftartikkel; Peer reviewed, 2016-06-17)
      Background: The regional lymph node involvement is a major prognostic factor in patients with non-small cell lung cancer (NSCLC) undergoing surgical resection. Disease relapse is common, suggesting that early disseminated disease is already present in the regional lymph nodes at the time of surgery, and that the current nodal staging classification might be suboptimal. Early detection of disseminated ...

    • High number of kinome-mutations in non-small cell lung cancers associated with reduced immune response and poor relapse-free survival 

      Helland, Åslaug; Brustugun, Odd Terje; Nakken, Sigve; Halvorsen, Ann Rita; Dønnem, Tom; Bremnes, Roy M.; Busund, Lill-Tove; Sun, Jinchang; Lorenz, Susanne; Solberg, Steinar; Jørgensen, Lars Hilmar; Vodak, Daniel; Myklebost, Ola; Hovig, Eivind; Meza, Leonardo Zepeda (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-04-07)
      Lung cancer is the leading cause of cancer related death, and the past years’ improved insight into underlying molecular events has significantly improved outcome for specific subsets of patients. In particular, several new therapies that target protein kinases have been implemented, and many more are becoming available. We have investigated lung cancer specimens for somatic mutations in a targeted ...

    • Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway 

      Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne; Berg, Thomas; Bjørge, Line; Blix, Egil Støre; Bjerkehagen, Bodil; Brabrand, Sigmund; CAMERON, MARTE; Dalhaug, Astrid; Dietzel, Dalia; Dønnem, Tom; Enerly, Espen; Flobak, Åsmund; Fluge, Sverre; Gilje, Bjørnar; Gjertsen, Bjørn Tore; Grønberg, Bjørn Henning; Grønås, Kari; Guren, Tormod Kyrre; Hamre, Hanne Mari; Haug, Åse; Heinrich, Daniel; Hjortland, Geir Olav; Hovig, Eivind; Hovland, Randi; Iversen, Ann-Charlotte; Janssen, Emiel; Kyte, Jon A; Gythfeldt, Hedda; Lothe, Ragnhild Adelheid; Lund, Jo-Åsmund; Meza, Leonardo Zepeda; Munthe-Kaas, Monica Cheng; Nguyen, Olav Toai Duc; Niehusmann, Pitt; Nilsen, Hilde; Puco, Katarina; Ree, Anne Hansen; Riste, Tonje Bøyum; Semb, Karin; Steinskog, Eli Sihn Samdal; Stensvold, Andreas; Suhrke, Pål; Tennøe, Øyvind Krohn; Tjønnfjord, Geir Erland; Vassbotn, Liv Jorunn; Aas, Eline; Aasebø, Kristine Øverås; Tasken, Kjetil; Smeland, Sigbjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-05-14)
      Background: Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed attention has arisen due to recent advancements in cancer diagnostics including access to high-throughput sequencing of tumour tissue. Targeted therapies interfering with cancer ...

    • Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial 

      Rakaee, Mehrdad; Andersen, S.; Giannikou, K.; Paulsen, Erna-Elise; Kilvær, Thomas Karsten; Rasmussen Busund, Lill-Tove; Berg, Thomas; Richardsen, Elin; Lombardi, Ana Paola; Adib, E.; Pedersen, Mona Irene; Tafavvoghi, Masoud; Wahl, Sissel Gyrid Freim; Petersen, R.H.; Bondgaard, A.L.; Yde, C.W.; Baudet, C.; Licht, P.; Lund-Iversen, Marius; Grønberg, Bjørn Henning; Fjellbirkeland, Lars; Helland, Åslaug; Pøhl, M.; Kwiatkowski, D.J.; Dønnem, Tom (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-04-24)
      Background - We aim to implement an immune cell score model in routine clinical practice for resected non-small-cell lung cancer (NSCLC) patients (NCT03299478). Molecular and genomic features associated with immune phenotypes in NSCLC have not been explored in detail.<p> <p>Patients and methods - We developed a machine learning (ML)-based model to classify tumors into one of three categories: ...

    • Mutasjonstesting ved ikke-småcellet lungekreft 

      Brustugun, Odd Terje; Helland, Åslaug; Fjellbirkeland, Lars; Kleinberg, Lilach; Ariansen, Sarah Louise; Jebsen, Peter Wilhelm; Scott, Helge; Dønnem, Tom; Bremnes, Roy M.; Berg, Thomas; Grønberg, Bjørn Henning; Dai, Hong Yan; Wahl, Sissel Gyrid Freim; Mangseth, Kjersti; Helgeland, Lars (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-04-30)
      Bakgrunn. Epidermal vekstfaktorreseptor (EGFR) tyrosinkinasehemmere (EGFR-TKI) er en relativt ny klasse legemidler til behandling av ikke-småcellet lungekreft. Den nasjonale faggruppen for lungekreft, Norsk Lunge Cancer Gruppe, anbefaler at pasienter med ikke-småcellet lungekreft testes for mutasjoner i EGFRgenet. Vi rapporterer her erfaringene som er gjort etter at slik testing ble innført i ...

    • Nye sentre skal gi flere kliniske studier i Norge 

      Skoie, Inger Marie; Skogås, Jan Gunnar; Langø, Thomas; Myhr, Kjell-Morten; Myhre, Peder Langeland; Goll, Rasmus; Fretland, Signe Øien; Helland, Åslaug (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-01-20)
      Seks NorTrials-sentre for behandlingsforskning er etablert ved universitetssykehusene. Målet er å øke antallet kliniske studier og forbedre pasientbehandlingen.

    • Osteopontin is a prognostic biomarker in non-small cell lung cancer 

      Rud, Ane Kristine Kongsgaard; Pedersen, Kjetil Boye; Øijordsbakken, Miriam; Lund-Iversen, Marius; Halvorsen, Ann Rita; Solberg, Steinar; Berge, Gisle; Helland, Åslaug; Brustugun, Odd Terje; Mælandsmo, Gunhild (Journal article; Tidsskriftartikkel; Peer reviewed, 2013)
      Background: In a previously published report we characterized the expression of the metastasis-associated proteins S100A4, osteopontin (OPN) and ephrin-A1 in a prospectively collected panel of non-small cell lung cancer (NSCLC) tumors. The aim of the present follow-up study was to investigate the prognostic impact of these potential biomarkers in the same patient cohort. In addition, circulating ...

    • Protein kinase C isozymes associated with relapse free survival in non-small cell lung cancer patients 

      Halvorsen, Ann Rita; Haugen, Mads Haugland; Øjlert, Åsa Kristina; Lund-Iversen, Marius; Jørgensen, Lars Hilmar; Solberg, Steinar; Mælandsmo, Gunhild Mari; Brustugun, Odd Terje; Helland, Åslaug (Journal article; Tidsskriftartikkel, 2020-11-25)
      <i>Introduction</i>: Protein expression is deregulated in cancer, and the proteomic changes observed in lung cancer may be a consequence of mutations in essential genes. The purpose of this study was to identify protein expression associated with prognosis in lung cancers stratified by smoking status, molecular subtypes, and EGFR-, TP53-, and KRAS-mutations.<p> <p><i>Methods</i>: We performed ...

    • Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23–24, 2023 

      Ringborg, Ulrik; von Braun, Joachim; Celis, Julio; Baumann, Michael; Berns, Anton; Eggermont, Alexander; Heard, Edith; Heitor, Manuel; Chandy, Mammen; Chen, Chien-Jen; Costa, Alberto; De Lorenzo, Francesco; De Robertis, Edward M.; Dubee, Frederick Charles; Ernberg, Ingemar; Gabriel, Mariya; Helland, Åslaug; Henrique, Rui; Jönsson, Bengt; Kallioniemi, Olli; Korbel, Jan; Krause, Mechthild; Lowy, Douglas R.; Michielin, Olivier; Nagy, Peter; Oberst, Simon; Paglia, Vincenzo; Parker, M. Iqbal; Ryan, Kevin; Sawyers, Charles L.; Schüz, Joachim; Silkaitis, Katherine; Solary, Eric; Thomas, David; Turkson, Peter; Weiderpass Vainio, Elisabete; Yang, Huanming (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-12-22)
      Analyses of inequalities related to prevention and cancer therapeutics/care show disparities between countries with different economic standing, and within countries with high Gross Domestic Product. The development of basic technological and biological research provides clinical and prevention opportunities that make their implementation into healthcare systems more complex, mainly due to the growth ...